Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved
Make real-time adjustments to keep things moving in the right direction
No approved reviews yet
Add GHK-Cu to your regimen Talk to a provider about whether GHK-Cu fits your skin renewal or tissue repair goals and how to run it safely
Semaglutide helps manage blood sugar levels by mimicking a hormone called GLP-1 (glucagon-like peptide-1)
Low-income subsidies also do not apply to Bridge prescriptions
US$ 21.39
US$ 21.01
US$ 23.81
US$ 27.80
US$ 21.52
US$ 21.44
US$ 29.67
US$ 28.55
US$ 21.81
US$ 26.14
